These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 37828249)
21. Malaria vaccine: a step toward elimination. Jindal H; Bhatt B; Malik JS; Sk S; Mehta B Hum Vaccin Immunother; 2014; 10(6):1752-4. PubMed ID: 24643280 [TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Bejon P; White MT; Olotu A; Bojang K; Lusingu JP; Salim N; Otsyula NN; Agnandji ST; Asante KP; Owusu-Agyei S; Abdulla S; Ghani AC Lancet Infect Dis; 2013 Apr; 13(4):319-27. PubMed ID: 23454164 [TBL] [Abstract][Full Text] [Related]
24. The March Toward Malaria Vaccines. Hoffman SL; Vekemans J; Richie TL; Duffy PE Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S319-33. PubMed ID: 26590432 [TBL] [Abstract][Full Text] [Related]
25. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi. Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527 [TBL] [Abstract][Full Text] [Related]
26. [Development and application of the world's first malaria subunit vaccine RTS, S/AS01]. Xu WY Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):557-559. PubMed ID: 35128883 [TBL] [Abstract][Full Text] [Related]
27. Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives. Saied AA; Metwally AA; Dhawan M; Choudhary OP; Aiash H EMBO Mol Med; 2022 Aug; 14(8):e16287. PubMed ID: 35758210 [TBL] [Abstract][Full Text] [Related]
28. [Development of malaria vaccines-state of the art]. Metzger WG; Sulyok Z; Theurer A; Köhler C Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):45-55. PubMed ID: 31828371 [TBL] [Abstract][Full Text] [Related]
29. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study. Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R Elife; 2022 Jan; 11():. PubMed ID: 35060479 [TBL] [Abstract][Full Text] [Related]
30. [Potential challenges for large-scale uses of RTS, S/AS01 vaccine in malaria-endemic areas]. Feng GQ Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):553-554. PubMed ID: 35128881 [TBL] [Abstract][Full Text] [Related]
31. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
33. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466 [TBL] [Abstract][Full Text] [Related]
34. [Prospects and reflections on the research and development of next-generation malaria vaccines]. Xiao B; Huang ZH; Jiang LB Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Jan; 33(6):555-556. PubMed ID: 35128882 [TBL] [Abstract][Full Text] [Related]
35. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331 [TBL] [Abstract][Full Text] [Related]
36. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials]. Cohen J; Benns S; Vekemans J; Leach A Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995 [TBL] [Abstract][Full Text] [Related]
37. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. Camponovo F; Ockenhouse CF; Lee C; Penny MA BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924 [TBL] [Abstract][Full Text] [Related]
38. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607 [TBL] [Abstract][Full Text] [Related]